Delaware-based Med Dev has obtained $775,000 in private financing and hopes to raise $2.225 million more. The startup will use the money to conduct further research and pursue FDA approval for its devices, which are intended to help eliminate nasal methicillin-resistant Staphylococcus aureus colonization without the need for antibiotics.

Full Story:

Related Summaries